Decreased p27(Kip1) expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma

Hepatology

Volumn 30, Issue 5, 1999, Pages 1167-1173

  Hui, Ai Min ^a   Cui, Xing ^a   Makuuchi, Masatoshi ^a   Li, Xin ^a   Shi, Ya Zhou ^a   Takayama, Tadatoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN P27;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CELL CYCLE PROTEINS; CELL NUCLEUS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE-FREE SURVIVAL; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0032713810     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300506     Document Type: Article

References (16)

1. Hui A-M, Makuuchi M. Molecular basis of multistep hepatocarcinogenesis: genetic and epigenetic events. Scand J Gastroenterol 1999; in press.
2. Teh M, Wee A, Path MRC, Raju GC. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. Cancer Res 1994;74:1542-1545.
3. Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cacner: correlation with tumor grade and survival. HEPATOLOGY 1995;22: 774-779.
4. Suto T, Sugai T, Nakamura S, Funato O, Nitta H, Sasaki R, Kanno S, et al. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Cancer 1998;82:86-95.
5. INK4B/MTS2 genes in biliary tract cancers. Cancer Res 1995;55:2756-2760.
6. Kipl and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-225.
7. Kipl protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-230.
8. Kipl and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A 1997;94:6380-6385.
9. Loda M, Cukor B, Tam SW, Lavin P, Piorentino M, Draetta GF, Jessup JM, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcijnomas. Nat Med 1997;3:231-234.
10. Kipl levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998;90:916-920.
11. Kipl is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-548.
12. Kipl and apotosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma. Cancer 1998;85:1711-1718.
13. Kipl expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer 1998;85:1250-1260.
14. Kipl expression and progression of human esophageal squamous cell carcinoma. Int J Cancer 1998;79:439-443.
15. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman JL, Cangi MG, Signortti S, et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998;58:1730-1735.
16. Kipl in human lung cancer: differential changes in small cell and non-small cell carcinomas. Cancer Res 1998;58:1042-1047.